Erschienen in:
23.08.2019 | Original Article – Clinical Oncology
Therapeutic outcome and prognostic factors in sinonasal rhabdomyosarcoma: a single-institution case series
verfasst von:
Wanpeng Li, Hanyu Lu, Dehui Wang
Erschienen in:
Journal of Cancer Research and Clinical Oncology
|
Ausgabe 11/2019
Einloggen, um Zugang zu erhalten
Abstract
Background
The purpose of this study was to explore the demographics, multimodality therapeutic outcomes*** and prognostic factors in sinonasal rhabdomyosarcoma (SNRMS).
Methods
We conducted a retrospective analysis of 40 patients who underwent treatment of SNRMS from March 2007 to March 2018. The Kaplan–Meier method and the log-rank test were used to assess survival rates. The Cox regression model was used for multivariate survival analysis.
Results
In total, 25 males and 15 females were included in the study; the median age was 33 years (range, 2–67 years). All patients underwent surgical resection, and surgery prior to or after adjuvant therapy (chemotherapy and radiotherapy) was performed in 91.4% of the patients. The overall 1-, 3- and 5-year survival rates were 77.0%, 46.5% and 46.5%, respectively, during a mean follow-up time of 27.9 (range, 2–128) months in all patients. The log-rank test showed Intergroup Rhabdomyosarcoma Study (IRS) group and infiltration of the skull base influenced overall survival (p = 0.001; p = 0.022). Advanced IRS stage, lymph node metastasis and tumor size ≥ 5 cm were also associated with an unfavorable outcome on overall survival (p = 0.01; p = 0.035; p = 0.02). The results of multivariate regression analysis showed patients with IRS group I were associated with better prognosis outcome on overall survival.
Conclusion
Patients with SNRMS have poor 5-year overall survival, and IRS group is the independent prognostic factor for overall survival.